

Disclosures

Personal Commercial (11)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Atropos Health	Consultant Fees/Honoraria	Modest (< \$5,000)	Other
Bitterroot	Consultant Fees/Honoraria	Modest (< \$5,000)	Vascular Medicine
BridgeBio	Consultant Fees/Honoraria	Modest (< \$5,000)	Other
Bristol-Myers Squibb Company	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
CSL Behring	Research/Research Grants ‡ AEGIS2	Significant (>= \$5,000)	Acute Coronary Syndromes Prevention
Cytokinetics	Officer, Director, Trustee, or other Fiduciary Role	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Edwards Lifesciences	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Element Science	Consultant Fees/Honoraria	Modest (< \$5,000)	Arrhythmias and Clinical EP General Cardiology
Foresight	Consultant Fees/Honoraria	Significant (>= \$5,000)	Other
Janssen Pharmaceuticals, Inc	Research/Research Grants ‡ Trials in planning process (3 trials)	Significant (>= \$5,000)	Acute Coronary Syndromes Arrhythmias and Clinical EP Other
WebMD	Consultant Fees/Honoraria	Significant (>= \$5,000)	General Cardiology Other

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (2)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
American Heart Association	Officer, Director, Trustee, or other Fiduciary Role	None (\$0)	Other
College of the Holy Cross, Worcester MA	Officer, Director, Trustee, or other Fiduciary Role	None (\$0)	Other

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (1)

Funding Source	Institutional Compensation Level
Weill Cornell Medicine	Significant (>= \$5,000)

Expert Witness Testimony (1)

Year	Case Title	Represented	Description	Compensation
Self				
2021	Clinical practice guidelines	Defendant ‡ Lawfirm: Porter and Arnold	Question regarding clopidogrel and strength of evidence regarding its position in guidelines.	Significant (>= \$5,000)

‡ Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 9/21/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 9/21/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 9/21/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 9/21/2023

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.